skip to Main Content

Passionate about Science

World-class drug discovery expertise
and an unprecedented track record with 4 drugs on the market

Passionate about Science

World-class drug discovery expertise
and an unprecedented track record with 4 drugs on the market

IRBM to collaborate with MSD to develop peptides against coronavirus

IRBM to collaborate with MSD to develop peptides against coronavirus

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)

21st July 2020, Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2. The parties will collaborate in hit to lead optimization and preclinical drug development to rapidly advance selected candidates towards the clinic.

WHYUS

We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.

NewsEvents

Comparison Of Different Protein Precipitation And Solid‐phase Extraction Protocols For The Study Of The Catabolism Of Peptide Drugs By LC‐HRMS
IRBM used liquid chromatography-high resolution mass spectrometry to explore different methods for the study of catabolism (breakdown) which is a key driver in the design of more stable peptides.
read more

BIO Digital

Ready to race? Come talk to us at BIO Digital from 8-12th June in our virtual drug discovery pavilion. IRBM are an innovative research organization working across all aspects of drug discovery and early development for different modalities – small molecule, peptides and antibodies.

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

Pomezia, Italy - Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

In Memory of Maurizio Botta: His Vision of Medicinal Chemistry

IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.

IRBMPHOTOS

IRBMVIDEOS

Back To Top